Skip to main content

Advertisement

Log in

The Clinical and Histological Spectrum of Idiopathic Inflammatory Myopathies

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of myositis, characterised by chronic muscle weakness, cutaneous features, different extra-muscular manifestations and circulating autoantibodies. IIMs included classical polymyositis (PM), dermatomyositis (DM) and other different types of myositis with a wide range of muscle involvement. A complete autoantibody profile and a muscle biopsy are mandatory to correctly diagnose different clinical entities and to define their different prognosis. Bohan and Peter’s criteria included five items to diagnose adult onset PM and DM. The sensitivity was 74–100 %, while the specificity is low, due to a poor ability to differentiate PM from neuromuscular diseases. Other criteria included a more accurate histological definition of PM, DM or amyopathic DM, obtaining a higher specificity. Autoantibodies’ association, interstitial lung disease and clinical cardiac involvement represent the main items that could define the prognosis of these patients. On the other hand, inclusion body myositis is a different myopathy characterised by a peculiar muscle mass involvement, muscle atrophy and progressive loss of function, due to complete failure to all immunosuppressive drugs used. Treatment of IIMs is based on corticosteroids (CS), which show rapid clinical response and functional improvement. Different immunosuppressant drugs are given to obtain a better control of the disease during CS tapering dose. No controlled double blind trials demonstrated the superiority of one immunesuppressant on another. The occurrence of interstitial lung involvement requires the immediate introduction of immunosuppressants in addiction to CS. Severe dysphagia seems to improve with intravenous immunoglobulins (Ig). Physical therapy could be started after the acute phase of diseases and seems to have a beneficial role in muscle strength recovery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Dalakas M (1991) Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 325:1487–1498

    Article  CAS  PubMed  Google Scholar 

  2. Dalakas M, Hohlfeld R (2003) Polymyositis and dermatomyositis. Lancet 362:971–982

    Article  CAS  PubMed  Google Scholar 

  3. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292:403–407

    Article  CAS  PubMed  Google Scholar 

  4. Hoogendijk J, Amato A, Lecky B, Choy E, Lundberg I, Rose M et al (2004) 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 14:337–345

    Article  PubMed  Google Scholar 

  5. Hochberg MC (1988) Epidemiology of polymyositis/dermatomyositis. Mt Sinai J Med 55:447–452

    CAS  PubMed  Google Scholar 

  6. Targoff IN, Miller FW, Medsger TA Jr, Oddis CV (1997) Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheum 9:527–535

    Article  CAS  Google Scholar 

  7. Garlepp MJ, Mastaglia FL (2008) Inclusion body myositis: new insights into pathogenesis. Curr Opin Rheumatol 20:662–668

    Article  PubMed  Google Scholar 

  8. Linklater H, Pipitone N, Rose MR et al (2013) Classifying idiopathic inflammatory myopathies: comparing the performance of six existing criteria. Clin Exp Rheumatol 31:767–769

    PubMed  Google Scholar 

  9. Love LA, Leff RL, Fraser DD et al (1991) A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 70:360–374

    Article  CAS  Google Scholar 

  10. Tanimoto K, Nakano K, Kano S et al (1995) Classification criteria for polymyositis and dermatomyositis. J Rheumatol 22:668–674

    CAS  PubMed  Google Scholar 

  11. Troyanov Y, Targoff IN, Tremblay JL et al (2005) Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine 84:231–249

    Article  PubMed  Google Scholar 

  12. Troyanov Y, Targoff IN, Payette MP et al (2014) Redefining dermatomyositis: a description of new diagnostic criteria that differentiate pure dermatomyositis from overlap myositis with dermatomyositis features. Medicine (Baltimore) 93:318–332

    Article  Google Scholar 

  13. van der Kooi AJ, de Visser M (2014) Idiopathic inflammatory myopathies. Handb Clin Neurol 119:495–512

    Article  PubMed  Google Scholar 

  14. Furst DE, Amato AA, Iorga SR, Gajria K, Fernandes AW (2012) Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle Nerve 45:676–683

    Article  PubMed  Google Scholar 

  15. Carstens PO (2013) Diagnosis, pathogenesis and treatment of myositis: recent advances. Clin Exp Immunol 175:349–358

    Article  Google Scholar 

  16. Meyer A, Meyer N, Schaeffer N, Gottenberg JE, Geny B, Sibilia J (2015) Incidence and prevalence of inflammatory myopathies: a systematic review. Rheumatology 54:50–63

    Article  PubMed  Google Scholar 

  17. Medsger TA, Oddis CV (1997) Inflammatory muscle disease. Clinical features. In J.H. Klippel, P.A. Dieppe (ed) Rheumatology. Mosby 2nd edition volume 2. pp. 7.13.1-13

  18. Ebert EC (2010) Review article: the gastrointestinal complications of myositis. Aliment Pharmacol Ther 1:359–65

    Article  Google Scholar 

  19. Blane CE, White SJ, Braunstein EM, Bowyer SL, Sullivan DB (1984) Patterns of calcification in childhood dermatomyositis. Am J Roentgenol 142:397–400

    Article  CAS  Google Scholar 

  20. Balin SJ, Wetter DA, Andersen LK, Davis MD (2012) Calcinosis cutis occurring in association with autoimmune connective tissue disease: the Mayo Clinic experience with 78 patients, 1996–2009. Arch Dermatol 148:455–462

    Article  CAS  PubMed  Google Scholar 

  21. Shimizu M, Ueno K, Ishikawa S et al (2014) Role of activated macrophage and inflammatory cytokines in the development of calcinosis in juvenile dermatomyositis. Rheumatology (Oxford) 53:766–767

    Article  Google Scholar 

  22. Mamyrova G, O’Hanlon TP, Sillers L et al (2008) Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis Rheum 58:3941–3950

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Avouac J, Guerini H, Wipff J et al (2006) Radiological hand involvement in systemic sclerosis. Ann Rheum 65:1088–1092

    Article  CAS  Google Scholar 

  24. Farzaneh-Far A, Proudfoot D, Weissberg PL et al (2000) Matrix gla protein is regulated by a mechanism functionally related to the calcium-sensing receptor. Biochem Biophys Res Commun 27:736–740

    Article  Google Scholar 

  25. van Summerer MJH, Spliet WGM, Royen-Kerkhof A et al (2008) Calcinosis in juvenile dermatomyositis: a possible role for the vitamin K-dependent protein matrix gla protein. Rheumatology 47:267–271

    Article  Google Scholar 

  26. Weinel S, Callen JP (2004) Calcinosis cutis complicating adult-onset dermatomyositis. Arch Dermatol 140:365–366

    Article  PubMed  Google Scholar 

  27. Bowyer SL, Blane CE, Sullivan DB, Cassidy JT (1983) Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcifi cation. J Pediatrics 103:882–888

    Article  CAS  Google Scholar 

  28. Pachman LM, Hayford JR, Chung A et al (1998) Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheum 25:1198–1204

    CAS  PubMed  Google Scholar 

  29. Sallum AM, Pivato FC, Doia-Filho U et al (2008) Risk factors associated with calcinosis of juvenile dermatomyositis. J Pediatr (Rio J) 84:68–74

    Article  Google Scholar 

  30. Gunawardena H, Wedderburn LR, Chinoy H et al (2009) Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 60:1807–1814

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Valenzuela A, Chung L, Casciola-Rosen L et al (2014) Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis. JAMA Dermatol 150:724–729

    Article  PubMed  PubMed Central  Google Scholar 

  32. Ceribelli A, Fredi M, Taraborelli M et al (2012) Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther 14:R97

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Hervier B, Devilliers H, Stanciu R et al (2012) Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmunity Rev 12:210–217

    Article  CAS  Google Scholar 

  34. Lega JC, Reynaud Q, Belot A, Fabien N, Durieu I, Cottin V (2015) Idiopathic inflammatory myopathies and the lung. Eur Respir Rev 24:216–238

    Article  PubMed  Google Scholar 

  35. Cottin V, Thivolet-Béjui F, Reynaud-Gaubert M et al (2003) Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J 22:245–250

    Article  CAS  PubMed  Google Scholar 

  36. Kurasawa K, Nawata Y, Takabayashi K et al (2002) Activation of pulmonary T cells in corticosteroid-resistant and -sensitive interstitial pneumonitis in dermatomyositis/polymyositis. Clin Exp Immunol 129:541–548

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Fathi M, Vikgren J, Boijsen M et al (2008) Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum 59:677–685

    Article  PubMed  Google Scholar 

  38. Hayashi S, Tanaka M, Kobayashi H et al (2008) High-resolution computed tomography characterization of interstitial lung diseases in polymyositis/dermatomyositis. J Rheumatol 35:260–269

    PubMed  Google Scholar 

  39. Schwarz MI (1992) Pulmonary and cardiac manifestations of polymyositis-dermatomyositis. J Thorac Imaging 7:46–54

    Article  CAS  PubMed  Google Scholar 

  40. Hochberg MC, Feldman D, Stevens MB (1986) Adult onset polymyositis/dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature. Sem Arthritis Rheum 15:168–178

    Article  CAS  Google Scholar 

  41. Gottdiener JS, Sherber HS, Hawley RJ, Engel WK (1978) Cardiac manifestations in polymyositis. Am J Cardiol 41:1141–1149

    Article  CAS  PubMed  Google Scholar 

  42. Gonzales Lopez L, Gamez-Nava JI, Sanchez L et al (1996) Cardiac manifestations in dermato-polymyositis. Clin Exp Rheumatol 14:373–379

    Google Scholar 

  43. Denbow CE, Lie T, Trancredi RG, Bunch TW (1979) Cardiac involvement in polymyositis: a clinicopathologic study of 20 autopsied patients. Arthritis Rheum 22:1088–1092

    Article  CAS  PubMed  Google Scholar 

  44. Mahrholdt H, Goedecke C, Wagner A et al (2004) Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 109:1250–1258

    Article  PubMed  Google Scholar 

  45. Taylor AJ, Wortham DC, Burge JR, Rogan KM (1993) The heart in polymyositis: a prospective evaluation of 26 patients. Clin Cardiol 16:802–808

    Article  CAS  PubMed  Google Scholar 

  46. Coblyn JS, Weinblatt ME (1997) Rheumatic diseases and the heart. In: Braunwald E (ed) Heart disease. A textbook of cardiovascular medicine. WB Saunders & Co, Philadelphia, pp 1779–80

    Google Scholar 

  47. Riemekasten G, Opitz C, Audring H et al (1999) Beware of the heart, the multiple picture of cardiac involvement in myositis. Rheumatol 1999(38):1153–1157

    Article  Google Scholar 

  48. Stern R, Godbold JH, Chess Q, Kagen LJ (1984) ECG abnormalities in polymyositis. Arch Intern Med 144:2185–2189

    Article  CAS  PubMed  Google Scholar 

  49. Lie JT (1995) Cardiac manifestations in polymyositis/dermatomyositis: how to get to the heart of the matter. J Rheumatol 22:809–811

    CAS  PubMed  Google Scholar 

  50. Kuhl U, Lauer B, Souvatzoglu M, Vosberg H, Schultheiss HP (1998) Antimyosin scintigraphy and immunohistologic analysis of endomyocardial biopsy in patients with clinically suspected myocarditis: evidence of myocardial cell damage and inflammation in the absence of histologic signs of myocarditis. J Am Coll Cardiol 32:1371–1376

    Article  CAS  PubMed  Google Scholar 

  51. Arahata K, Engel AG (1986) Monoclonal antibody analysis of mononuclear cells in myopathies III: immunoelectron microscopy aspects of cell-mediated muscle fibre injury. Ann Neurol 19:112–125

    Article  CAS  PubMed  Google Scholar 

  52. Dalakas MC (2002) Muscle biopsy findings in inflammatory myopathies. Rheum Dis Clin N Am 28:779–798

    Article  Google Scholar 

  53. Mastaglia FL (2009) Sporadic inclusion body myositis: variability in prevalence and phenotype and influence of MHC. Acta Myol 28:66–71

    CAS  PubMed  PubMed Central  Google Scholar 

  54. Needham M, Corbett A, Day T et al (2008) Prevalence of sporadic inclusion body myositis and factors contributing of delayed diagnosis. J Clin Neurosci 15:1350–1353

    Article  PubMed  Google Scholar 

  55. Mastaglia FL, Needham M (2015) Inclusion body myositis: a review of clinical and genetic aspects, diagnostic criteria and therapeutic approaches. J Clin Neurosci 22:6–13

    Article  PubMed  Google Scholar 

  56. Jackson CE, Barohn RJ, Gronseth G et al (2008) Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity. Muscle Nerve 37:473–476

    Article  CAS  PubMed  Google Scholar 

  57. Hokkoku K, Sonoo M, Higashihara M, Stålberg E, Shimizu T (2012) Electromyographs of the flexor digitorum profundus muscle are useful for the diagnosis of inclusion body myositis. Muscle Nerve 46:181–186

    Article  PubMed  Google Scholar 

  58. Tasca G, Monforte M, De Fino C, Kley RA, Ricci E, Mirabella M (2015) MRI pattern recognition in sporadic inclusion body myositis. Muscle Nerve. doi:10.1002/mus.24661, Mar 25

    Google Scholar 

  59. Hengstman GJ, ter Laak HJ, Vree Egberts WT et al (2006) Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 65:1635–1238

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Casciola-Rosen LA (2011) Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme a reductase (HMGCR) in patients with statin-associated autoimmune myopathy. Arthritis Rheum 63:713–721

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Levin MI, Mozaffar T, Al-Lozi MT, Pestronk A (1998) Paraneoplastic necrotizing myopathy: clinical and pathological features. Neurology 50:764–767

    Article  CAS  PubMed  Google Scholar 

  62. Dimitri D, Andre C, Roucoules J, Hosseini H, Humbel RL, Authier FJ (2007) Myopathy associated with anti-signal recognition peptide antibodies: clinical heterogeneity contrasts with stereotyped histopathology. Muscle Nerve 35:389–395

    Article  PubMed  Google Scholar 

  63. Euwer RL, Sontheimer RD (1991) Amyopathic dermatomyositis (dermatomyositis sine myositis) presentation of six new cases and review of the literature. J Am Acad Dermatol 24:959–966

    Article  CAS  PubMed  Google Scholar 

  64. Sontheimer RD (2002) Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 46:626–436

    Article  PubMed  Google Scholar 

  65. Morganroth PA, Kreider ME, Okawa J, Taylor L, Werth VP (2010) Interstitial lung disease in classic and skin-predominant dermatomyositis: a retrospective study with screening recommendations. Arch Dermatol 146:729–738

    Article  PubMed  PubMed Central  Google Scholar 

  66. Cao H, Parikh TN, Zheng J (2009) Amyopathic dermatomyositis or dermatomyositis-like skin disease: retrospective review of 16 cases with amyopathic dermatomyositis. Clin Rheumatol 28:979–984

    Article  PubMed  Google Scholar 

  67. Mukae H, Ishimoto H, Sakamoto N et al (2009) Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest 136:1341–1347

    Article  PubMed  Google Scholar 

  68. Suda T, Fujisawa T, Enomoto N et al (2006) Interstitial lung diseases associated with amyopathic dermatomyositis. Eur Respir J 28:1005–1012

    Article  CAS  PubMed  Google Scholar 

  69. Iaccarino L, Gatto M, Bettio S et al (2013) Overlap connective tissue disease syndromes. Autoimmunity Review 12:363–373

    Article  CAS  Google Scholar 

  70. Lega JC, Cottin V, Fabien N, Thivolet-Béjui F, Cordier JF (2010) Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl- tRNA synthetase autoantibodies: a similar condition? J Rheumatol 37:1000–1009

    Article  CAS  PubMed  Google Scholar 

  71. Rigolet A, Musset L, Dubourg O et al (2012) Inflammatory myopathies with anti-Ku antibodies: a prognosis dependent on associated lung disease. Medicine (Baltimore) 91:95–102

    Article  CAS  Google Scholar 

  72. Cavazzana I, Fredi M, Taraborelli M, Quinzanini M, Tincani A, Franceschini F (2013) A subset of systemic sclerosis but not of systemic lupus erythematosus is defined by isolated anti-Ku autoantibodies. Clin Exp Rheumatol 31:118–121

    PubMed  Google Scholar 

  73. Dayal NA, Isenberg DA (2002) SLE/myositis overlap: are the manifestations of SLE different in overlap disease? Lupus 11:293–298

    Article  CAS  PubMed  Google Scholar 

  74. Vancsa A, Gergely L, Ponyi A et al (2010) Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: relevance for clinical classification: retrospective study of 169 patients. Joint Bone Spine 77:125–130

    Article  CAS  PubMed  Google Scholar 

  75. Cavagna L, Nuño L, Scirè CA, AENEAS (American, European NEtwork of Antisynthetase Syndrome) collaborative group et al (2015) Clinical spectrum time course in anti Jo-1 positive antisynthetase syndrome: results from an international retrospective multicenter study. Medicine (Baltimore) 94:e1144

    Article  CAS  Google Scholar 

  76. Aguila LA, Ugolini Lopes MR, Zon Pretti F et al (2014) Clinical and laboratory features of overlap syndromes of idiopathic inflammatory myopathies associated with systemic lupus erythematosus, systemic sclerosis, or rheumatoid arthritis. Clin Rheumatol 33:1093–1098

    Article  PubMed  Google Scholar 

  77. Mathur T, Manadan AM, Thiagarajan S, Hota B, Block JA (2014) Serum transaminases are frequently elevated at time of diagnosis of idiopatic inflammatory myopathy and normalize with creatine kinase. J Clin Rheumatol 20:130–132

    Article  PubMed  Google Scholar 

  78. Lott JA, Landesman PW (1984) The enzymology of skeletal muscle disorders. Crit Rev Clin Lab Sci 20:153–190

    Article  CAS  PubMed  Google Scholar 

  79. Fujimoto M, Sato S, Ihn H, Kikuchi K, Yamada N, Takehara K (1995) Serum aldolase level is a useful indicator of disease activity in eosinophilic fasciitis. J Rheumatol 22:563–565

    CAS  PubMed  Google Scholar 

  80. Quintero-Del Rio AI, Punaro M, Pascual V (2002) Faces of eosinophilic fasciitis in childhood. J Clin Rheumatol 8:99–103

    Article  PubMed  Google Scholar 

  81. Nozaki K, Pestronk A (2009) High aldolase with normal creatine kinase in serum predicts a myopathy with perimysial pathology. J Neurol Neurosurg Psychiatry 80:904–908

    Article  CAS  PubMed  Google Scholar 

  82. Casciola Rosen L, Hall JC, Mammen AL, Christopher-Stine L, Rosen A (2012) Isolated elevation of aldolase in the serum of myositis patients: a potential biomarker of damaged early regenerating muscle cells. Clin Exp Rheumatol 30:548–553

    PubMed  PubMed Central  Google Scholar 

  83. Rieder LG, Werth VP, Huber AM et al (2011) Measures for adult and juvenile dematomyositis, polymyositis, and inclusion body myositis. Arthritis Care Res 63:S118–S157

    Article  Google Scholar 

  84. Miller FW, Rider LG, Chung YL et al (2001) Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology 40:1262–1273

    Article  CAS  PubMed  Google Scholar 

  85. Ruperto N, Ravelli A, Pistorio A et al (2008) The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 59:4–13

    Article  PubMed  Google Scholar 

  86. Rieder LG, Koziol D, Giannini EH et al (2010) Validation of manual muscle testing and a subset of eight muscles (MMT8) for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res 62:465–472

    Article  Google Scholar 

  87. Rieder LG, Giannini EH, Harris-Love M et al (2003) Defining clinical improvement in adult and juvenile myositis. J Rheumatol 30:603–617

    Google Scholar 

  88. Hay EM, Bacon PA, Gordon C et al (1993) The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 86:447–458

    CAS  PubMed  Google Scholar 

  89. Dimachkie MM, Barohn RJ (2012) Idiopathic inflammatory myopathies. Sem Neurol 32:227–236

    Article  Google Scholar 

  90. Bunch TW, Worthington JW, Combs JJ, Ilstrup DM, Engel AG (1980) Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Intern Med 92:365–369

    Article  CAS  PubMed  Google Scholar 

  91. Dalakas MC, Illa I, Dambrosia JM et al (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993–2000

    Article  CAS  PubMed  Google Scholar 

  92. Vencovský J, Jarosová K, Machácek S et al (2000) Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 29:95–102

    Article  PubMed  Google Scholar 

  93. Miller J, Walsh Y, Saminaden S, Lecky BRF, Winer JB (2002) Randomised double blind controlled trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy. J Neurol Sci 199:S53

    Google Scholar 

  94. Villalba L, Hicks JE, Adams EM et al (1998) Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 41:392–399

    Article  CAS  PubMed  Google Scholar 

  95. WITHDRAWN: immunosuppresant and immunomodulatory treatment dor dermatomysitis and polymyositis (2009) Cochrane database Syst Rev 7: CD003643. Doi: 10.1002/14561858

  96. Danieli MG, Malcangi G, Palmieri C et al (2002) Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis 61:37–42

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Rose MR, Jones K, Leong K et al (2015) Treatment for inclusion body myositis. Cochrane Database Syst Rev 30;6: CD001555. doi: 10.1002/14651858.CD001555

  98. Alexanderson H, Lundberg IE (2012) Exercise as a therapeutic modality in patients with idiopathic inflammatory myopathies. Curr Opin Rheumatol 24:201–207

    Article  PubMed  Google Scholar 

  99. Lundberg IE, Vencovsky J, Alexandreson H (2014) Therapy of myositis: biological and physical. Curr Opin Rheumatol 26:704–711

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ilaria Cavazzana.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cavazzana, I., Fredi, M., Selmi, C. et al. The Clinical and Histological Spectrum of Idiopathic Inflammatory Myopathies. Clinic Rev Allerg Immunol 52, 88–98 (2017). https://doi.org/10.1007/s12016-015-8517-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-015-8517-4

Keywords

Navigation